23 July, 2014 04:50 IST
News
Sun Pharma to acquire US-based DUSA Pharma
Source: IRIS (08-NOV-12)
Comments  |  Post Comment

Sun Pharmaceutical Industries, an integrated pharmaceutical company and DUSA Pharmaceuticals, Inc. have entered into a definitive agreement under which Sun Pharma (Q,N,C,F)* will acquire DUSA, a dermatology company focused on developing and marketing its Levulan photodynamic therapy platform.

Under the terms of the agreement, a 100% subsidiary of Sun Pharmaceutical Industries  will commence a tender offer for all of the outstanding common stock of DUSA at a price of USD 8 a share in cash, a 38% premium to the closing price of DUSA’s common stock on November 07, 2012. The transaction has a total cash value of approximately USD 230 million.

Dilip Shanghvi, managing director of the company said, “DUSA has proven technical capabilities in photodynamic skin treatments, with USFDA approved manufacturing.  DUSA’s business brings us an entry into dermatological treatment devices, where we see good growth opportunities.”

“We believe this transaction brings significant value to DUSA shareholders and are pleased that Sun Pharma recognized the value that has been created. The entire team at DUSA has built an excellent franchise around Levulan PDT and continues to grow its presence in the dermatology space.  We are  confident that Sun Pharma will build upon the solid foundation our organization has established in the United States dermatology market to further expand access to Levulan for patients with actinic kerotoses,” stated Robert Doman, president and CEO of DUSA Pharmaceuticals, Inc.  

Shares of Sun Pharmaceutical Industries declined Rs 5.3, or 0.76%, to settle at Rs 696.15. The total volume of shares traded was 220,055 at the BSE (Thursday).


News
K P I T Technologies standalone quarterly profit up 16.83% - 22-Jul-2014 18:50
Jindal Hotels standalone quarterly earnings plummet 76.15% - 22-Jul-2014 17:52
Rane Brake Lining standalone quarterly profit surges 46.49% - 22-Jul-2014 17:49
'Buy' Idea Cellular; target Rs 170: ICICIdirect - 22-Jul-2014 17:47
Ind-Ra affirms Allahabad Bank at 'AA'; outlook stable - 22-Jul-2014 17:15
Tide Water Oil enters into JV with JX Nippon Oil - 22-Jul-2014 16:58
TCS inks pact with MapR Technologies - 22-Jul-2014 16:51
ING Vysya Bank Q1 profit falls 18% - 22-Jul-2014 16:38
Kirloskar Brothers swings to loss in Apr-Jun quarter - 22-Jul-2014 16:22
Axis Bank Q1 profit climbs 18.3% on lower provisions - 22-Jul-2014 16:19
Angel Broking upgrades target price of Indoco Remedies to Rs 192 - 22-Jul-2014 15:41
more...
* Q - Quote , N - News , C - Chart , F - Financials
Comments Post comment 
By: Vishal | 9 November 2012 Reply | Forward | Report Abuse 
The acquistion would lead to tremendous synergies. The product portfolio of DUSA is growing @25%, which is much faster than the dermat market in the US. Sun would further accelerate the revenue growth by leveraging the field force of their subsidiary Taro, which is a major player in dermatology in the US. This article is extremely informative http://pharmadeals.pharmaintellect.com/2012/11/sun-acquires-dusa-transaction-valuation.html
 Post Comment
Name Email
Comment
Security Code type   xjd9y4 into this box
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Forums  |   E-mail  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer